SCHEMBL7039619

SCHEMBL7039619

C#Cc1cc(C)cc(O)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.55
ACHE P22303 4/20 0.40
HCAR1 Q9BXC0 1/20 0.40
SELL P14151 1/20 0.40
SELP P16109 1/20 0.40
SELE P16581 1/20 0.40
CYP3A4 P08684 3/20 0.34
TDP1 Q9NUW8 3/20 0.34
POLB P06746 3/20 0.34
ALOX15 P16050 2/20 0.34
MAOA P21397 2/20 0.34
CYP1A1 P04798 2/20 0.34
CYP1B1 Q16678 2/20 0.34
TP53 P04637 2/20 0.34
MAPT P10636 2/20 0.34
APEX1 P27695 2/20 0.34
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
PTP4A3 O75365 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL718437 0.82 BACE1 (0.50) ALDH1A1ACHECYP3A4CYP1A1CYP1B1
SCHEMBL2807680 0.82 BACE1 (0.41) ALDH1A1CYP3A4CYP1A1CYP1B1HSD17B10
SCHEMBL6554977 0.82 ALDH1A1 (0.40) ALDH1A1ACHESELLSELPSELE
SCHEMBL12535886 0.78 ALDH1A1 (0.57) ALDH1A1ACHEHCAR1SELLSELP
SCHEMBL29450984 0.76 ALDH1A1 (0.55) ALDH1A1ACHEHCAR1SELLSELP
SCHEMBL509567 0.76 ALDH1A1 (0.55) ALDH1A1ACHEHCAR1SELLSELP
SCHEMBL25140237 0.76 IDH1 (0.34) ALDH1A1KMT2AMEN1
SCHEMBL12535841 0.73 APP (0.50) ALDH1A1ACHEHCAR1SELLSELP
Orcinol SCHEMBL68497 0.73
SCHEMBL11574035 0.73 ALDH1A1 (1.00) ALDH1A1ACHEHCAR1SELLSELP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4085059-B1 HETEROARYL COMPOUNDS AS INHIBITORS OF PROGRAMMED NECROSIS PATHWAY, COMPOSITION AND METHOD USING THE SAME ACCRO BIOSCIENCE HK LTD (HK) 2024-03-20 EP disclosed
US-20230121233-A1 Heteroaryl compounds as inhibitors of programmed necrosis pathway, composition and method using the same ACCRO BIOSCIENCE (HK) LIMITED (HK) 2023-04-20 US disclosed
WO-2021138694-A1 HETEROARYL COMPOUNDS AS INHIBITORS OF PROGRAMMED NECROSIS PATHWAY, COMPOSITION AND METHOD USING THE SAME ACCRO BIOSCIENCE INC. (KY) 2021-07-08 WO disclosed
US-9878045-B2 Triorthogonal reagents for dual protein conjugation REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2018-01-30 US disclosed
US-20030065117-A1 Modified silicone compound, process of producing the same, and cured object obtained therefrom NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2003-04-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230121233-A1 Heteroaryl compounds as inhibitors of programmed necrosis pathway, composition and method using the same BAX, PDCD1, PDCD4 ALDH1A1 3695/4885ACHE 4365/4885HCAR1 1137/4885
US-20030065117-A1 Modified silicone compound, process of producing the same, and cured object obtained therefrom ORMDL3, SGMS1, HEATR1 ALDH1A1 2270/4885ACHE 3607/4885HCAR1 1038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.